Results 171 to 178 of about 2,098 (178)

Idarucizumab: A Review as a Reversal Agent for Dabigatran

American Journal of Cardiovascular Drugs, 2016
Idarucizumab (Praxbind(®)), a humanized monoclonal antibody, is a specific reversal agent for the direct oral thrombin inhibitor dabigatran, available as its prodrug dabigatran etexilate (Pradaxa(®)). Idarucizumab is approved in several countries (including the USA, the EU, Canada and Australia) for use in adult patients on dabigatran when the reversal
openaire   +3 more sources

Idarucizumab for the Reversal of Dabigatran

Annals of Emergency Medicine, 2017
Michael Gottlieb, Basem F. Khishfe
openaire   +3 more sources

Idarucizumab

pharma-kritik, 2017
Dieses Medikament wirkt der Antikoagulation durch den direkten Thrombinhemmer Dabigatran entgegen. Sein praktischer Nutzen ist aber bisher nicht genügend dokumentiert. Da auch sein Nebenwirkungspotential noch nicht geklärt ist, kann die Verwendung dieses sehr teuren Mittels wohl am ehesten noch im Rahmen weiterer Studien verantwortet werden.
openaire   +1 more source

Failure of dabigatran following idarucizumab and omeprazole administration

Internal Medicine Journal, 2021
Karim M. Mahawish, Almond Leung
openaire   +3 more sources

Idarucizumab for Dabigatran Reversal Guideline

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2016
David P. Reardon, Kent A. Owusu
openaire   +3 more sources

Concerns about idarucizumab for dabigatran reversal

Blood Coagulation & Fibrinolysis, 2016
Birke Schneider, Josef Finsterer, Claudia Stöllberger, Peter Pommer   +3 more
openaire   +3 more sources

Letter in response to “Idarucizumab for dabigatran overdose”

Clinical Toxicology, 2016
Eric Villeneuve, Josh J. Wang, Sophie Gosselin   +2 more
openaire   +3 more sources

Idarucizumab bewährt sich im Praxisalltag

InFo Neurologie & Psychiatrie, 2016
openaire   +2 more sources